Business
Cibus is an agricultural biotechnology company using proprietary gene editing to develop plant traits for seed-company customers.
Cibus cut its FY2025 loss and cash burn, but revenue fell and equity dropped sharply in a tiny-revenue gene-editing model.
The read at a glance✓ Audited against SEC data
- Business mix — Gene-edited crop traitsNote
- Revenue — $3.6M, -14.6%Watch
- Net income — ($127.1M), loss narrowedWatch
- FCF — ($51.2M), improvedWatch
- Equity — $21.8M, -76.3%Watch
- Insiders — 0 purchases and 0 salesNote
- Accounting — Altman weak; Beneish clean; EQ greyWatch
Where the revenue comes from
Fiscal 2025, as Cibus, Inc. reports it. History and quarterly detail are in the app.
- Reportable$3.6M
Leadership changes
From Cibus, Inc.'s own filings, the day they're filed.
- Thomas Urban · chief executive officer · appointmenteff. 2026-04-07
- Craig Wichner · Directors · appointmenteff. 2025-11-05
- Kimberly A. Box · directors · appointmenteff. 2025-09-11
Latest filings
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-08-13
- 8-K · Company announcement2026-06-09
- 8-K · Company announcement2026-06-05
- 8-K · Company announcement2026-05-14
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Cibus, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.